The short version
- Why people research itFocus, memory, neuroprotection, mood and stress resilience.
- What the evidence isApproved for moderate to severe Alzheimer's dementia, and that is the whole indication — not mild disease, not age-related forgetfulness.
- What to watchNew hallucinations, agitation or confusion.
How Memantine works
The mechanism is a filter, not a switch, and the whole drug follows from that. The label states it plainly: memantine acts as a low to moderate affinity uncompetitive open-channel NMDA receptor antagonist Memantine label 2025.
What it is approved for, and it is narrower than the shelf it is sold on. The indication is moderate to severe dementia of the Alzheimer's type Memantine label 2025. Not mild.
That combination blocks the steady background leak of a chronically over-activated receptor while stepping aside for the brief bursts that carry a signal. It is the only widely used dementia drug acting on the glutamate side rather than by raising acetylcholine, which is why it is studied in combination with the cholinesterase inhibitors rather than against them.
- Oral
On the goal map: Glutamatergic & synaptic plasticity (Focus, memory & cognition)
Research on Memantine7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Approved for moderate to severe Alzheimer's dementia. In the largest pooled dataset it did not reach the reviewers' own threshold for a clinically important effect as a single agent.
Human clinical evidence
Approved for moderate to severe Alzheimer's dementia, and that is the whole indication — not mild disease, not age-related forgetfulness. An individual-patient network meta-analysis of 80 randomized trials in 21,138 adults set 1.40 MMSE points as its threshold for a clinically important difference and reports that every regimen cleared it EXCEPT single-agent rivastigmine, galantamine and memantine (Veroniki 2022).
A 2026 Bayesian network meta-analysis of 125 trials in more than 30,000 people put memantine at a standardized mean difference of 0.24 and donepezil at 0.21 — while aerobic exercise scored 0.55 and cognitive training 0.45 in the same network (Li 2026). The authors are careful that the non-drug arms are short-term and adjunctive rather than substitutes.
Nobody has ever tested it in cognitively normal adults. Every participant in both syntheses carried a dementia diagnosis.
Correlative data
The Cochrane review of stopping these drugs pooled six trials and 759 participants and states that no trial assessed withdrawal of memantine alone (Parsons 2021). Anyone starting it without a prescriber has no published basis for deciding when or how to stop.
The 2025 dementia guideline recommends it strongly for moderate to severe Alzheimer's disease and separately from the cholinesterase inhibitors, because it acts on a different transmitter system (Kim 2025).
How the mechanism reads
A low-to-moderate affinity uncompetitive open-channel NMDA antagonist: it can only enter a channel glutamate has already opened and leaves again quickly, which blocks a chronic background leak while stepping aside for signal-carrying bursts.
MechanisticThe interaction nobody warns this audience about. Its label states renal clearance falls about 80% under alkaline urine at pH 8. Sodium bicarbonate loading before hard intervals does exactly that, on a drug with a 60-80 hour half-life — so the result is accumulation, and the presentation of too much of it is confusion.
Mechanistic
Sources
- U.S. Food and Drug Administration. DailyMed, U.S. National Library of Medicine; Carlsbad Technology Inc. label version 2, revised February 2025
- Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open 2022 · PMID 35473731
- Li Y, Li L, Yang Q, Xiong J. Comparative Efficacy and Safety of Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Current Alzheimer Research 2026 · PMID 42099163
- Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews 2021 · PMID 35608903
- Kim Y, Kang DW, Kim GH, et al. (Korean Dementia Association). Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dementia and Neurocognitive Disorders 2025 · PMID 39944527
Memantine safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Severe kidney impairment: it is cleared by the kidney and builds up.
- Seizure history: NMDA blockers can lower seizure threshold in some people.
- Taking dextromethorphan, ketamine or amantadine: other NMDA blockers stack side effects.
- Urine alkalinizing agents or very alkaline urine: they slow its clearance.
- Pregnancy or breastfeeding: NMDA blockade in a developing brain is untested.
What’s expected
- Dizziness or light confusion early, from open-channel NMDA blockade.
- Headache, constipation or sleepiness in the first weeks.
- Smoothing of background mental noise rather than a stimulant effect.
Watch for
- New hallucinations, agitation or confusion.
- A seizure or fainting spell.
- Marked swelling, breathlessness or very slow heartbeat.
- Passing little or no urine.
Labs that tell you it’s working
- Cystatin C with eGFR
- Comprehensive Metabolic Panel (CMP)
- Vitamin B12 & Folate
- Urinalysis, Routine
Low-affinity uncompetitive NMDA channel blocker cleared by the kidney, so kidney function and urine pH set exposure.
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Memantine FAQ4 common questions
- Is Memantine approved for human use?
- Memantine is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Memantine researched for?
- Focus, memory, neuroprotection, mood and stress resilience.
- Which labs show whether it's doing anything?
- Cystatin C with eGFR; Comprehensive Metabolic Panel; Vitamin B12 & Folate; Urinalysis, Routine: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Memantine: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



